Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free IMM Stock Alerts

ImmuPharma (IMM) Competitors

ImmuPharma logo
GBX 3.74 +0.34 (+9.82%)
As of 11:58 AM Eastern
Compare

IMM vs. SCLP, MPH, 4BB, FARN, and OBI

Should you buy ImmuPharma stock or one of its competitors? ImmuPharma's main competitors and comparable companies include Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), 4basebio (4BB), Faron Pharmaceuticals Oy (FARN), and Ondine Biomedical (OBI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmuPharma compare to Scancell?

ImmuPharma (LON:IMM) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Comparatively, 15.5% of Scancell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ImmuPharma has a beta of 3.014, indicating that its stock price is 201% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, indicating that its stock price is 31% less volatile than the broader market.

ImmuPharma has a net margin of 3,519.56% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -353.21% -43.00%
Scancell -116.98%90.29%-45.28%

In the previous week, Scancell had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Scancell and 0 mentions for ImmuPharma. Scancell's average media sentiment score of 0.49 beat ImmuPharma's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company Overall Sentiment
ImmuPharma Neutral
Scancell Neutral

ImmuPharma has higher earnings, but lower revenue than Scancell. Scancell is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.37N/A
Scancell£4.71M21.33-£6.75M-£0.55N/A

Summary

ImmuPharma beats Scancell on 7 of the 12 factors compared between the two stocks.

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

ImmuPharma (LON:IMM) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

6.1% of ImmuPharma shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.37N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

ImmuPharma has a net margin of 3,519.56% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -353.21% -43.00%
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company Overall Sentiment
ImmuPharma Neutral
Mereo BioPharma Group plc (MPH.L) Neutral

Summary

ImmuPharma beats Mereo BioPharma Group plc (MPH.L) on 4 of the 7 factors compared between the two stocks.

How does ImmuPharma compare to 4basebio?

4basebio (LON:4BB) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

ImmuPharma has lower revenue, but higher earnings than 4basebio. ImmuPharma is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.69M44.82-£9.84M-£109.00N/A
ImmuPharmaN/AN/A-£2.51M-£0.37N/A

In the previous week, 4basebio had 4 more articles in the media than ImmuPharma. MarketBeat recorded 4 mentions for 4basebio and 0 mentions for ImmuPharma. 4basebio's average media sentiment score of 0.48 beat ImmuPharma's score of 0.00 indicating that 4basebio is being referred to more favorably in the media.

Company Overall Sentiment
4basebio Neutral
ImmuPharma Neutral

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
ImmuPharma 3,519.56%-353.21%-43.00%

4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.014, indicating that its share price is 201% more volatile than the broader market.

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 185.71%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than ImmuPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ImmuPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

4basebio beats ImmuPharma on 9 of the 15 factors compared between the two stocks.

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

ImmuPharma (LON:IMM) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for ImmuPharma. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat ImmuPharma's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company Overall Sentiment
ImmuPharma Neutral
Faron Pharmaceuticals Oy Positive

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.37N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

ImmuPharma has a beta of 3.014, indicating that its stock price is 201% more volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.121, indicating that its stock price is 12% more volatile than the broader market.

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -353.21% -43.00%
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

Summary

ImmuPharma beats Faron Pharmaceuticals Oy on 7 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Ondine Biomedical?

ImmuPharma (LON:IMM) and Ondine Biomedical (LON:OBI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

ImmuPharma has a beta of 3.014, suggesting that its share price is 201% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.308, suggesting that its share price is 69% less volatile than the broader market.

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 31.3% of Ondine Biomedical shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Comparatively, 29.0% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to Ondine Biomedical's net margin of -1,117.06%. ImmuPharma's return on equity of -353.21% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -353.21% -43.00%
Ondine Biomedical -1,117.06%-1,411.54%-159.71%

In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Company Overall Sentiment
ImmuPharma Neutral
Ondine Biomedical Neutral

Ondine Biomedical has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.37N/A
Ondine BiomedicalC$2.65M2,258.06-C$424.66K-C$6.00N/A

Summary

ImmuPharma and Ondine Biomedical tied by winning 5 of the 10 factors compared between the two stocks.

Get ImmuPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMM vs. The Competition

Export
MetricImmuPharmaBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£23.37M£4.06B£7.40B£2.92B
Dividend Yield0.77%3.61%2.53%6.17%
P/E Ratio-10.1211.42272.19367.32
Price / SalesN/A1,369.91631.7683,741.35
Price / Cash20.50108.3779.8927.89
Price / Book5.8016.8813.147.02
Net Income-£2.51M-£22.76M£3.47B£5.89B
7 Day Performance1.49%1.55%1.38%0.89%
1 Month Performance-16.78%11.70%8.62%3.27%
1 Year Performance135.53%56.88%25.90%22.28%

ImmuPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMM
ImmuPharma
N/AGBX 3.75
+9.8%		N/A+117.3%£23.37MN/AN/A13
SCLP
Scancell
N/AGBX 9.70
+1.5%		N/A-5.4%£100.67M£4.71MN/A51
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
4BB
4basebio
1.8112 of 5 stars		GBX 550
+4.8%		GBX 1,400
+154.5%		-44.4%£85.17M£1.69MN/A101
FARN
Faron Pharmaceuticals Oy
N/AGBX 39.60
-3.4%		N/A-81.4%£80.34MN/AN/A34

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IMM) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel